Stockreport

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 [Yahoo! Finance]

Kairos Pharma, Ltd.  (KAPA) 
PDF dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present at the European Society for Medical Oncology (ESM [Read more]